Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis

J D Cohen, S Zaltni, M J Kaiser, M C Bozonnat, C Jorgensen, J P Daurès, J Sany

ETANERCEPT, a soluble tumour necrosis factor α (TNFα) receptor fusion protein, may be combined with methotrexate (MTX) in severe rheumatoid arthritis (RA). Etanercept is generally given to patients treated with MTX who have an inadequate response. However, MTX could be introduced to patients who have already been treated with etanercept and who initially had a good response but subsequently a secondary failure. It was decided to evaluate, in an open prospective study, the clinical, biological, and functional benefit of the secondary addition of MTX in patients with RA with an inadequate response to etanercept alone.

PATIENTS, METHODS, AND RESULTS

A cohort of 93 patients with active and severe RA was observed for a mean duration of 8 months (range 1–20). The group comprised 75 women, 18 men, with an average age of 49.5 years (range 17–75), and positive rheumatoid factor in 67 (72%). All had been previously treated with a median of 49.5 years (range 17–75), and positive rheumatoid factor in 14 (78%) patients) had mean disease duration was 12.4 years (range 3–42). Patients were treated with subcutaneous injections of etanercept alone, 25 mg twice weekly. Eighteen of the 93 patients had an inadequate response (did not reach the American College of Rheumatology (ACR) 20 criteria, prerequisite for inclusion in this cohort) with etanercept alone; we therefore added MTX to the treatment, no other DMARDs being allowed. The mean dose of added MTX was 15.5 mg a week. The dosage was given orally to 12 patients and intramuscularly to the remaining six. All 18 patients (16 female, two male, average age 51 years, mean disease duration 13.3 years, with a positive rheumatoid factor in 14 (78%) patients) had previously received MTX before etanercept alone, but it had produced an insufficient result. This failure with MTX was a requirement before starting etanercept. A prospective follow up of these patients took place every month for 3 months and from then on every 3 months during a 12 month period, with recording of the usual clinical and biological measures in order to obtain the ACR20, 50, and 70 and the Disease Activity Score 28 (DAS28). This enabled us to assess the efficacy of this addition. The Health Assessment Questionnaire (HAQ) was also used in this study.

Table 1 summarises the results obtained. The data show an improvement in disease activity, which was sustained through the 12 month follow up. A favourable response was obtained at 3 months with 10 (56%) achieving the ACR20, 5 (28%) the ACR50, and 2 (11%) the ACR70. At 12 months of this combination therapy, 12 (67%) had achieved the ACR20, 9 (50%) the ACR50, and 3 (17%) the ACR70. DAS28 decreased from 4.9 to 3.0 at 3 months and to 2.4 at 1 year, suggesting a significant clinical improvement in disability. The HAQ score changed from 1.7 to 1.1 at 1 year.

There was also a rapid therapeutic biological response, with a decrease in the erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) of 50% after 3 months. No serious adverse events were reported and only two patients required antibiotics (bronchitis, urinary infection).

DISCUSSION

In summary, this open study suggests that the secondary addition of MTX to etanercept produced a marked improvement among patients who had had an inadequate response to etanercept alone after a first inadequate response to MTX given alone. To our knowledge, this is the first open study to evaluate the efficacy of MTX in addition to etanercept in a two step strategy. Previous studies have demonstrated the efficacy of etanercept alone compared with MTX, its efficacy in early RA or in addition to methotrexate, and, in particular, in juvenile idiopathic arthritis. This suggests that when MTX is added to the etanercept regimen patients with RA improve both clinically and biologically without any increase in side effects. The addition of MTX to the treatment of patients who respond incompletely to etanercept alone may be useful in the management of RA. It will be interesting to evaluate this strategy in further studies. Therefore, the preferred treatment

Table 1 Results of secondary addition of MTX to etanercept

<table>
<thead>
<tr>
<th>MTX duration (months)</th>
<th>0</th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>12</th>
<th>Friedman; p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR20 (%)</td>
<td>56</td>
<td>61</td>
<td>67</td>
<td>67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR50 (%)</td>
<td>28</td>
<td>28</td>
<td>39</td>
<td>50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR70 (%)</td>
<td>11</td>
<td>6</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28, mean</td>
<td>4.9</td>
<td>3.0</td>
<td>2.9</td>
<td>2.8</td>
<td>2.4</td>
<td>0.0017</td>
</tr>
<tr>
<td>Score HAQ, mean</td>
<td>1.7</td>
<td>1.3</td>
<td>1.2</td>
<td>1.2</td>
<td>1.1</td>
<td>0.0081</td>
</tr>
<tr>
<td>ESR (mm/1st h), mean</td>
<td>49.1</td>
<td>33.2</td>
<td>30.6</td>
<td>33.8</td>
<td>27.2</td>
<td>0.1266</td>
</tr>
<tr>
<td>CRP (mg/l), mean</td>
<td>56.6</td>
<td>24.0</td>
<td>13.8</td>
<td>17.1</td>
<td>12.3</td>
<td>0.0001</td>
</tr>
</tbody>
</table>
Blunted coronary flow reserve in systemic sclerosis: a sign of cardiac involvement in asymptomatic patients

A Sulli, M Ghio, G P Bezante, L Deferrari, C Craviotto, V Sebastiani, M Setti, G Filaci, F Puppo, A Barsotti, M Cutolo, F Indiveri

Cardiac disease is often present in systemic sclerosis (SSc), even if rarely of clinical significance. Therefore, we investigated the coronary flow reserve (CFR), by transthoracic contrast enhanced second harmonic Doppler echocardiography, a non-invasive method that might detect early heart dysfunction in patients with SSc even in the absence of clinical signs or symptoms.

Twenty nine consecutive patients (2 male, 27 female, mean (SD) age 55 (14) years) affected by SSc,45 not complaining of signs or symptoms of cardiovascular involvement, were recruited. No further serious disease other than SSc was present. Eleven healthy subjects matched for age and sex (CFR mean (SD) age 53 (5) years) were also evaluated as controls. Echocardiography was performed with an ultrasound unit using a broadband transducer with second harmonic capability in both B mode and Doppler modality. Levovist was used as the ultrasound contrast agent.67 The CFR, expressed as the ratio between hyperaemic (peak adenosine infusion) and resting, both peak, diastolic velocity (PdvCFR) and velocity time integral (VtiCFR), was non-invasively assessed in the distal left anterior descending coronary. Peripheral microangiopathy was assessed by nailfold videocapillaroscopy (NVC), as previously reported.8

All patients were found in sinus rhythm, without any significant ECG alteration. All ECG parameters were normal. The study showed a reduced CFR in 14/29 patients with SSc, when compared with the normal range of healthy subjects matched for age and sex (CFR >2.83).7 In particular, both PdvCFR and VtiCFR, were strongly reduced in patients with SSc (mean (SD) 1.93 (0.56) and 1.81 (0.56), respectively) in comparison with controls (3.11 (0.72) and 2.83 (0.51), respectively) (p < 0.0001). Furthermore, both PdvCFR and VtiCFR were significantly lower in patients with diffuse SSc (1.74 (0.46) and 1.59 (0.38), respectively) than in patients with limited SSc (2.39 (0.52) and 2.35 (0.38), respectively) (p < 0.004 and p < 0.001, respectively) (fig 1).

Nineteen patients (mean (SD) age 52 (13) years) and 10 patients (mean (SD) age 63 (12) years) had diffuse SSc (dSSc) and limited SSc (lSSc), respectively; the patients with dSSc were younger than those with ISSc (p < 0.04).

Glucose serum levels were normal in all patients with SSc. No statistically significant correlation was found between CFR and history of smoking and cholesterol or triglyceride serum levels. Moreover, no statistically significant correlation was found between CFR and blood pressure values.

REFERENCES

Figure 1 CFR in patients with SSc and controls (Cntr), assessed by transthoracic contrast enhanced second harmonic Doppler and expressed as the ratio between hyperaemic and resting, both peak, diastolic velocity (PdvCFR) (A) and velocity time integral (VtiCFR) (B), dSSc, patients with diffuse SSc; lSSc, patients with limited SSc.
Incidentally discovered asymptomatic necrotising intra-abdominal vasculitis after peripheral gastric bypass surgery for morbid obesity

A Boungas, M Melachrinou, G Giannopoulos, N Meimaris, P Aroukatos, F Kalfarentzos, A P Andonopoulos

We describe the case of a 35 year old woman, who underwent peripheral gastric bypass type Roux-Y surgery for morbid obesity, and was incidentally discovered to have diffuse abdominal necrotising vasculitis, which has remained silent for at least 15 months.

CASE REPORT

The patient was referred to us because a biopsy of the appendix removed at surgery had disclosed necrotising vasculitis (fig 1), and her serology had shown positive antinuclear antibodies (ANA), 1/320 homogeneous. She had received bronchodilators in the past, amoxicillin clavulanate, oral contraceptives, and fenfluramine for a short time. No recent vaccination had been administered. She denied systemic symptoms, arthralgias or arthritis, skin or mucosal lesions, abdominal pain or rectal bleeding, sicca symptoms, or Raynaud’s phenomenon. After surgery she had lost 45 kg and, as expected, she had been experiencing mild abdominal cramps and diarrhoea shortly after meals. Physical examination was normal.
DISCUSSION

Vasculitis of the PAN type, localised to the appendix or the gall bladder, has been accidentally found, usually after surgery.\(^1\) Its prognosis is almost always good, in contrast with vasculitis that is found when systemic PAN has already been diagnosed.\(^1\) Several possibilities can be suggested for the aetiology of the diffuse intra-abdominal vasculitis of our patient. Firstly, a relationship with the operation can be easily excluded because the disease was already present in the appendix before the procedure.

A second possibility may implicate the morbid obesity of the patient. Intra-abdominal processes such as pancreatitis and malignancy, but other systemic diseases also, such as infectious endocarditis, atrial myxoma, and drug abuse, have been reported to mimic the visceral angiographic appearance of vasculitis.\(^2\) No such problems were present, and furthermore, morbid obesity has never been reported to cause vasculitis.

The positive ANA may suggest systemic lupus erythematosus as a third possibility, but our patient had no other evidence to support this diagnosis.

Drug induced vasculitis may be a fourth possibility.\(^3\) In the vast majority of cases it affects the skin, but it may extend to internal organs. The diagnosis is usually one of exclusion and a timely relationship to the offending drug should be documented. Almost any drug can be blamed. However, it is rather unlikely that one of the drugs the patient had taken would have induced abdominal vasculitis, without skin manifestations.

Finally, it is quite likely that our patient had asymptomatic PAN, which will either remain as such, or will become manifest in the future. In such cases, clinicians should be aware of the possibility that a systemic necrotising vasculitis may, for some time, remain asymptomatic. Furthermore, mesenteric angiography, when used to help diagnose PAN in cases of multisystem clinical presentations, is not expected to disclose vasculitis when hepatic enzymes are normal,\(^2\) but even then the procedure may be of diagnostic help.

Figure 1  Small artery of the appendiceal wall, showing fibrinoid necrosis of the intima, and inflammatory infiltrate, consisting predominantly of lymphocytes in and around the vessel wall (haematoxylin and eosin ×400, original magnification).

Figure 2  Multislice CT angiography of the abdomen. Obstruction of the superior mesenteric artery 6 cm after its origin and for 1.5 cm is noted, followed by reinfusion, supplemented by a large jejunal arterial branch, originating above the obstruction. Narrowing of the latter is seen at about its middle. Several jejunal branches of the superior mesenteric artery disclose stenoses at multiple sites, followed by mild dilatation (bead-like configuration). A small narrowing can be seen at the first portion of the right renal artery as well.

Authors’ affiliations
A Bounas, G Giannopoulos, N Meimaris, A P Andonopoulos, Department of Medicine, Division of Rheumatology, University of Patras School of Medicine, Patras, Greece
M Melachrinou, P Aroukatos, Department of Pathology, University of Patras School of Medicine, Patras, Greece
F Kalfarentzos, Department of Surgery, University of Patras School of Medicine, Patras, Greece

Correspondence to: Professor A P Andonopoulos, Internal Medicine and Rheumatology, University of Patras School of Medicine, 265 00 Rio, Patras, Greece; andandon@med.upatras.gr

Accepted 28 April 2003

REFERENCES
Ultrasound detection of knee patellar enthesitis: a comparison with magnetic resonance imaging

M Kamel, H Eid, R Mansour

The diagnosis of enthesitis in clinical practice is difficult and usually based on conventional radiographic findings, which are not helpful in most cases. We previously reported that ultrasound (US) was sensitive in detecting peculiar pathological features of enthesitis around the heel. Furthermore, we have continued to study the efficacy of ultrasonographic diagnosis of enthesitis of other tendon and ligament insertion sites.

METHODS AND RESULTS
Sixteen patients (10 male, six female, mean age 45.6 years) with a diagnosis of seronegative arthropathy were recruited from the population for the study. Their mean disease duration was 6.3 years. They had seronegative arthropathy and knee enthesopathy without typical conventional radiographic evidence. An HDI 3000 ATL US machine (Advanced Technology Laboratories, USA), equipped with a 12 MHz linear transducer, was used to examine the knee patellar enthesis.

The present study produced interesting findings (figs 1A and B). The US images of the knee patellar enthesis showed loss of the normal fibrillar echo texture of the patellar tendon, no homogeneous pattern, blurring of the patellar tendon margins, irregular focal or generalised increased tendon thickness, and focal ill-defined tendon defects, with loss of their tightly packed echogenic dots. The US images clearly showed the definition of the patellar tendon margins, which were more precise and anatomically defined than the magnetic resonance (MR) images (figs 1C and D).

DISCUSSION
The US examination of the knee joint clearly detected the early calcification foci of the patellar tendons. However, the calcification process of the knee patellar ligament developed less often in the patients than the calcification of the Achilles tendon found in a previous report.

The process of fatty degeneration of the patellar tendon was detected early in US images, and appears as hyperechoic intratendinous lesions.

This study detected a significant thickening of the patellar tendon, which can be measured by US. We believe that this US feature is more sensitive and reliable in diagnosing early enthesitis than a classical MR high signal intensity image.

Figure 1  (A) A sagittal US scan shows thickened proximal entheses of the patellar ligament with loss of its fibrillar echo pattern, loss of the sharp definition of its posterior aspect compared with the distal portion (arrow head), calcific foci (arrow). (B) A transverse US scan of the same patient shows the thickened medial part of the patellar ligament with calcific focus (arrow). (C) A sagittal T2 fat suppression image shows the thickened distal part of the patellar tendon with altered signal intensity (arrow head) and prepatellar bursitis (arrow). (D) A sagittal Pd weighted image shows high intensity signals of the proximal patellar tendon.
Longlasting effects of immunoadsorption in severe Sjögren’s syndrome

M Böhm, T Dörner, F Knebel, A Bruns, N Jochmann, G Baumann


Despite advances in understanding the immunopathogenesis of Sjögren’s syndrome, successful therapeutic interventions are extremely limited.

CASE REPORT

With this in mind we began an immunoadsorption treatment of a 38 year old woman, diagnosed 1.5 years ago with Sjögren’s syndrome. She reported dry eyes and mouth for several months and intermittent arthralgias, especially of the small finger joints and elbows, as well as swollen joints of the hands, elbows, and ankles for six years. During the six months before treatment her joint symptoms had increased significantly and considerably impaired everyday activities. A Schirmer’s test was positive. The antinuclear antibodies and rheumatoid factor were raised, autoantibodies against Ro/SSA and La/SSB were positive. Thus, the patient fulfilled four of six revised criteria of primary Sjögren’s syndrome.

Previous corticosteroid treatment (prednisolone 20 mg a day for four weeks) had led to opharyngeal candida mycosis, and methotrexate (25 mg a week) did not have a therapeutic effect. Because chloroquine had side effects in her family, the patient refused to take hydroxychloroquine. Upon presentation in our clinic, the patient took 5 mg a day of prednisolone. Because the severe arthralgias and sicca symptoms did not respond to conventional treatment we started to treat the patient with immunoadsorption, to improve the symptoms by reducing IgG to 10–20% of its initial level.

Approval of the ethics committee and informed consent by the patient were obtained, and we started immunoadsorption therapy according to a previous protocol used for patients with dilated cardiomyopathy. Immunoadsorption treatment took place in two consecutive cycles with an interval of four weeks. The first cycle comprised three treatment days and the second, two. The plasma filtration was similar to haemodialysis. The IgG-Therasorb Adsorber and a Miroisorb treatment unit (Plasmaselect, Teterow, Germany) treated 7 litres plasma a day. Plasma IgG, antibody complexes, and fragments of antibodies were bound to the Fc fragment of polyclonal sheep antihuman antibodies, bound in turn to Sepharose. After the first treatment cycle, the patient showed remarkable clinical improvement, with lessening of arthralgias and articular swelling, and subsequent increased joint mobility. The score for tender/swollen joints reduced from a value of 29 at the beginning to 0 at the end of the study. Complement factors C3 and C4 fell to 67% and 78% of baseline (0.8–0.6 g/l and 0.19–0.15 g/l), respectively. In addition, circulating immune complexes reduced to 29% (3.3–1.0 g/l) and the rheumatoid factor to 55% of initial value (2.5–1.4 g/l). The treatment reduced IgG from 24.31 to 6.24 g/l (2.5–1.4 g/l) and the rheumatoid factor to 55% of initial value (2.5–1.4 g/l). The treatment reduced IgG from 24.31 to 6.24 g/l (2.5–1.4 g/l) and the rheumatoid factor to 55% of initial value (2.5–1.4 g/l)

DISCUSSION

To prevent a rebound and infection after immunoadsorption, the treatment protocol requires intravenous IgG substitution (0.5 g per kg body weight Venimun) after each cycle, indicating that the patient’s IgG has a significant role in the disease. We cannot exclude the possibility that immunoglobulin infusion may have had some effect on the outcome. This needs to be examined by additional studies.
Juvenile temporal arteritis and activated protein C resistance

B Granel, J Serratrice, N Ene, P E Morange, P Disdier, P-J Weiller

Accepted 22 May 2003

REFERENCES
Takayasu's arteritis, and isolated vasculitis of the vasa vasorum. Histopathological analysis often discloses arterial thrombosis associated with non-giant cell, non-necrotising, and non-granulomatous vasculitis. A search for blood coagulation disorders has never been performed until now. Factor V Leiden is a well known risk factor for venous thrombosis but may also play a role in arterial thrombosis. This observation reminds doctors of this rare entity and highlights the need to study blood coagulation in cases of JTA.

Authors’ affiliations
B Granel, J Serratrice, N Ene, P Disdier, P-J Weiller, Service de Médecine Interne, Hôpital de la Timone, 264 rue Saint Pierre, 13385 Marseille, cedex 5, France
P E Moreng, Laboratoire d’Hématologie, Hôpital de la Timone, 264 rue Saint Pierre, 13385 Marseille, cedex 5, France

Correspondence to: Dr P Disdier; patrick.disdier@ap-hm.fr
Accepted 12 May 2003

Serum osteoprotegerin but not receptor activator of NF-κB ligand correlates with Larsen score in rheumatoid arthritis
M Skoumal, G Kolarz, W Wolosczuk, G Hawa, A Klingler

Osteoprotegerin (OPG) is a soluble decoy receptor, produced by osteoblastic cells and in the inflamed synovium of RA by dendritic cells, B cells, and other immunocompetent cells. It inhibits the differentiation of osteoclast precursor cells and the activation of mature osteoclasts by neutralising the receptor activator of NF-κB ligand (RANKL). RANKL, a member of the tumour necrosis factor family, is expressed on pre-osteoblasts and T lymphocytes. A soluble RANKL (sRANKL) can be produced by activated T lymphocytes or can be generated from the cell bound form by a protease. RANKL itself activates a receptor activator of NF-κB (RANK).

RANKL, together with monocyte-colony stimulating factor, interleukin 1, and RANK is responsible for osteoclast formation and activation and inhibits osteoclast apoptosis. Thus OPG acts as antagonist to RANKL. An imbalance of this system may play a part in the skeletal complications of rheumatoid arthritis (RA).

Our study aimed at comparing OPG and sRANKL in the serum of patients with RA. We identified 44 patients with RA (24 female, 20 male, mean age at manifestation of RA 49 years) with 60 measurements. Sixteen patients received low dose steroids, five patients showed generalised osteoporosis (x ray and/or osteodensitometry).

The results were analysed by Spearman correlation statistics and Wilcoxon two sample test. Serum OPG levels were measured in patients with RA using a sandwich-type enzyme linked immunosorbent assay

Table 1 Correlation of OPG and sRANKL with clinical data

<table>
<thead>
<tr>
<th>Clinical data</th>
<th>OPG</th>
<th>sRANKL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>sRANKL (pmol/l)</td>
<td>0.90</td>
<td>0.85</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>37.3</td>
<td>24.2</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>38.2</td>
<td>30.5</td>
</tr>
<tr>
<td>RF (U/l)</td>
<td>418.5</td>
<td>138</td>
</tr>
<tr>
<td>DAS</td>
<td>3.44</td>
<td>1.09</td>
</tr>
<tr>
<td>Larsen score</td>
<td>49.7</td>
<td>44.7</td>
</tr>
</tbody>
</table>

OPG, osteoprotegerin; sRANKL, soluble receptor activator of NF-κB ligand; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; RF, rheumatoid factor; DAS, disease activity score.

REFERENCES
Successful management of neonatal cryoglobulinaemia after a gemellar pregnancy in a woman with symptomatic type I cryoglobulinaemia

J Sibilia, O Feugues, V Laugel, A Dreal, J Messer, J Goetz

CASE REPORT

Since 1996 a 32 year old woman had had cold-induced clinical manifestations: Raynaud’s phenomenon, livedo reticularis, necrotic and purpuric lesions on the legs, and acrocyanosis on the ears and fingers. She had no family history of cold intolerance, autoimmune disease, or recurrent thrombosis. In 1998 these symptoms were traced to a monoclonal IgG\textsubscript{1} cryoglobulin (type I) present at 1.5 g/l and precipitating at 27°C. Cold agglutinin and cryofibrinogen were absent while total complement (CH\textsubscript{50}) and C4 fraction were low. There were no antinuclear, anti-dsDNA, anti-neutrophil, anti-cardiolipin, or anti-\beta\textsubscript{2}-glycoprotein I antibodies, and viral serology was negative for hepatitis B and C and cytomegalovirus. A skin biopsy showed leucocytoclastic vasculitis and thrombosis of the capillaries related to the cryoglobulin. There were no renal, gastrointestinal, or neurological manifestations, but the patient had intermittent distal polyarthritis and was treated with pentoxifylline accompanied by protective measures against cold.

This mother had born a first healthy child in 1996 and had experienced no previous miscarriage. In 2000, during a second dichorionic gestation of twins, the lesions were progressive while the cryoglobulin persisted at 1.1 g/l. Because the IgG\textsubscript{1} chain can cross the placenta and the initial temperature of cryoprecipitation was 27°C, clinical manifestations could be expected in the newborns at room temperature.

Authors’ affiliations
M Skoumal, G Kolarz, Institut fur Rheumatologie der Kurstadt Baden in Kooperation mit der Donauuniversität Krems, Rheumasonderkranananstalt der SVA der gewerblichen Wirtschaft, Baden, Austria
W Wołoszczuk; Ludwig Boltzmann Institut für experimentelle Endokrinologie, Vienna, Austria
G Hava, Biomedica Medizinprodukte GmbH & Co KG, Austria
A Klingler, Theoretical Surgery Unit, Department of General and Transplant Surgery, University Hospital, Innsbruck, Austria

Correspondence to: Dr M Skoumal, Rheumasonderkranananstalt der SVA der gewerblichen Wirtschaft, Adolfin Malchergasse 1, 2500 Baden, Austria; martin.skoumal@a1.net

Accepted 28 April 2003

REFERENCES


(ELISA) based on two OPG-specific antibody preparations. The mean value of a healthy control group of 170 blood donors is 2.2 pmol/l (2.0 pmol/l for men, 2.4 pmol/l for women).

sRANKL was measured by an enzyme catalysed colour change detectable on a standard ELISA reader. To measure only the biologically active form(s) of sRANKL biosynthetic OPG/Fc was used as capture protein. The mean value of serum sRANKL levels in healthy subjects was calculated as 1.3 pmol/l (median 0.9).

We detected serum levels of OPG with a mean value of 4.2 pmol/l (SD 2.0) and serum levels of RANKL with a mean value of 0.9 pmol/l (SD 0.8). We found a significant correlation between OPG and erythrocyte sedimentation rate (ESR) and OPG and the Larsen score but no correlation between RANKL and OPG or between RANKL and the clinical and radiological measures (table 1).

No significantly different OPG levels were found either in patients receiving steroids or in patients with osteoporosis.

In RA RANKL leads to bone erosions by activation of osteoclasts, and this process is inhibited by OPG. Therefore OPG seems to play an important part in preventing erosions and osteoporosis in patients with RA. Kolarz et al suggested that patients with active inflammation may show higher OPG values owing to activation of several other cells. Haynes et al showed an increased expression of RANKL in tissues surrounding bone erosions and at the same time OPG was absent in tissues from patients with active RA.

Despite the presence of raised serum OPG levels acting as protection mechanism, the local destructive effect of RANKL by activation of osteoclasts seems not to be fully balanced.

The up regulation of OPG might be a response to the inflammation; in contrast an up regulation of RANKL could not be found in the serum of patients with RA.

Haynes et al reported that OPG and RANKL behave differently depending on the cells which produce them. A further explanation may be the different strategies of both assays: the OPG assay measures free and bound OPG, the sRANKL assay only free sRANKL complexes formed from OPG and sRANKL would therefore be detected only with the OPG, but not with the sRANKL assay.
temperature. Treatment of the mother consisted only of
protection against cold. Plasmaphereses were not performed
as these do not totally eliminate cryoglobulin and have
potential drawbacks, such as inducing premature labour by
altering the plasma volume or hormone levels, or decreasing
fetal nutrients and maternal and fetal serum immunoglobu-
lin levels. General measures were defined to avoid cryopre-
cipitation at delivery: a room at 28°C, adapted clothes
permitting medical supervision, warming of liquids to 37°C
before perfusion to the mother, and placing the newborns in
incubators.

The twins (female and male weighing 2440 g and 2690 g,
respectively) were delivered after 39 weeks' gestation and
immediately put in incubators at 32°C. One and five minute
Apgar scores were 10 for both neonates, and no cutaneous or
visceral involvement was detected, despite the presence of
cryoglobulin at 1.70 g/l in cord blood. Two days later the
twins were placed in a room at 25°C, but after 3 hours small
erthrocyanotic maculae appeared on the boy’s fifth finger
(left hand) (fig 1) and second and fourth toes (left foot).
These lesions were very similar to those seen in the mother,
whereas careful examination of the girl disclosed no
pathological manifestations. The twins were replaced in
incubators and the lesions disappeared slowly within one
week.

After another 2 days they were removed from the
incubators and dressed warmly, no further lesions were observed and the dressing precautions could be gradually
abandoned before discharge. The monoclonal IgG1 cryoglo-
bulin was detected in the serum of both neonates at
comparesable levels, but it was unfortunately not possible to
obtain follow up of these results. Six months later the twins
were healthy while the mother’s status remained stable with
an unchanged serum cryoglobulin (1 g/l).

DISCUSSION
Maternal IgGs can cross the placenta, as is well illustrated by
certain neonatal autoimmune diseases related to maternal
autoantibodies.1 In the present case a monoclonal IgG1
cryoglobulin identified in the mother and her twin children
was associated with transient cold-induced lesions in one
child.2,3 This is the first report of a pathogenic neonatal effect
due to the transplacental passage of a type I cryoglobulin.
Although the lesions were probably favoured by the high
precipitation temperature (27°C), many other physicochem-
ical parameters can influence cryoprecipitation and hence
might explain the difference between the twins. Progressive clearance of the maternal IgG1 after its passive
transfer may further explain the favourable outcome and
absence of recurrence. Such cases are rare, probably on
account of the low incidence of type I cryoglobulinaemia in
women of child bearing age.5 Associations between preg-
nancy and other types of cryoglobulin have been described
but without related neonatal lesions.6,7 In a patient with
mixed type II cryoglobulin and hepatitis C infection,
cryoglobulinaemia was responsible for placental lesions
inducing pre-eclampsia, but no specific neonatal lesions were
seen.8

The consequences for the fetus of the transplacental
passage of IgG type I cryoglobulin are still unknown and the
management of such pregnancies is difficult owing to the
lack of a consensual procedure for the prevention of
maternofetal complications. Corticosteroids or immunosup-
pressive drugs have failed to demonstrate any benefit. In our
experience, protection against cold seems to be the only way
to avoid precipitation of the cryoglobulin in the vessels of
the mother and neonates with its pathogenic effects.

REFERENCES
1 Buyon JP, Kim MY, Copel JA, Friedman DM. Anti-Ro/SSA antibodies and
congenital heart block: necessary but not sufficient. Arthritis Rheum
2 Brouet JC, Clauser JP, Danon F, Klein M, Seligmann M. Biological and clinical
3 den Hollander JG, Swaak AJS. Essential cryoglobulinaemia (type 1) in three
patients characterised by Raynaud’s phenomenon, arthralgia-arthritis,
4 Cohen SJ, Pittlekow MR, Su WP. Cutaneous manifestations of
cryoglobulinaemia: clinical and histopathologic study of seventy-two patients.
6 Goodman GJ, Ryan PF, Sinclair RA. Post-partum nephrotic syndrome in mixed
7 Whitling DA. Systemic lupus erythematosus with cryoglobulinaemia,
peripheral gangrene, and transplacental passage of the LE factor: a case
8 Alberico S, Mazzia S, Grimaldi E, Valpe C, Cuashina S. Essential mixed type
II cryoglobulinaemia in a HCV positive pregnant woman: a case report. Clin
Primary Raynaud’s phenomenon in monozygotic twins

T Oskay, Ü Ölmez

We report two cases of primary Raynaud’s phenomenon in 16 year old monozygotic female twins.

CASE REPORT
The twins were admitted to the dermatology department with a one year history of the sudden onset of episodic purple lesions on both hands. Presentation of the lesions in the twins was synchronous. After careful questioning, we determined that it was usually induced by emotion or cold temperature. On dermatological examination, the order of purple discoloration, erythema, and pallor was observed symmetrically in both hands. There was no history of smoking, the use of drugs, occupational hazard, or trauma. They also had sensations of coolness and paraesthesia. Photographs of the hands were obtained during an attack and used to confirm the history. We also performed a provocative test—namely, immersion of the patient’s hand in ice water for three minutes, to confirm the diagnosis. Nailfold capillaroscopy examination also demonstrated normal capillaries. The female twins were born at 38 weeks of gestation by caesarean section. Obstetric anamnesis was normal. The twins’ past medical history was unremarkable. Their parents were relatives, but the family history was negative for cutaneous or collagen vascular disease.

Results of laboratory examinations, including complete blood count, biochemistry, urine analysis, thyroid function tests, serum cryoglobulins, complement levels, immunoglobulins, erythrocyte sedimentation rate, and C reactive protein, were normal. Serological testing for antinuclear antibody, anticardiolipin antibodies, and antibody to Ro, La, dsDNA, ribonucleoprotein, and Smith antigen were negative. The twins were diagnosed as monozygotic with almost complete certainty by examining the ABO blood type, HLA typing, fingerprints, and from the physical resemblance between them. Identical HLA antigens were HLA-A2, A24, B17, B57, Cw3, Cw6, DR4, and DR11. Medical evaluation subsequently disclosed no disorder known to cause secondary Raynaud’s phenomenon (RP).

DISCUSSION
RP is an exaggerated vascular response to cold temperature or emotional stress, primarily seen in young women. It is classified into primary or idiopathic without underlying disease and secondary when it is related to various medical problems.1, 2 Clinical criteria are used to distinguish between patients with uncomplicated or primary RP, and those with secondary RP. The suggested criteria for primary RP are symmetric attacks; the absence of tissue necrosis, ulceration or gangrene; the absence of a secondary cause on the basis of a patient’s history and general physical examination; normal nailfold capillaries; a negative test for antinuclear antibody; and a normal erythrocyte sedimentation rate.2, 3 The most common diseases associated with secondary RP are scleroderma, mixed connective tissue disease, systemic lupus erythematosus, occlusive vascular disease, drug effects, haematological abnormalities, and use of vibrating tools.2, 4

Primary RP occasionally evolves into a connective tissue disease, most commonly scleroderma.2, 4 Even though the cause of primary RP is not known, increased α2 sympathetic receptor activity on vessels, endothelial dysfunction, deficiency of calcitonin gene related peptide, protein-containing nerves, or some central thermo-regulatory defect have been implicated.5-6 A genetic cause for primary RP was first suggested by Lewis and Pickering, based on an apparent familial aggregation of primary RP.7, 8 MacGregor et al first assessed the genetic basis of RP in a population based twin study and found a substantial genetic contribution to the symptoms of RP.9 Recently, three potential candidate genes have been described in the genetic susceptibility to primary RP.9

To the best of our knowledge, this is the first report documenting the occurrence of primary RP in monozygotic twins. Association with HLA antigens, parental consanguinity, and development in identical twins may indicate that genetic factors have a role in the occurrence of this disease. Larger series of twins and investigation of multicase families are needed to clarify the genetic component in the pathogenesis of primary RP.

ACKNOWLEDGEMENT
We thank Omer Edip Erdemli MD, for his assistance in patient care.

Authors’ affiliations
T Oskay, Department of Dermatology Bayındır Medical Centre Ankara, Turkey
Ü Ölmez, Department of Clinical Immunology and Rheumatology, Ankara University Faculty of Medicine Ankara, Turkey

Correspondence to: Dr T Oskay, Mesa Park Sitesi Sedir Apt, Daire: 44 06400 Oran, Ankara, Turkey; tubooskay@hotmail.com

Accepted 27 March 2003

REFERENCES